Bayer looking at another year of 'resilience' before growth kicks in behind Nubeqa, Kerendia
4th March 2026 Uncategorised 0The primary growth drivers in Bayer’s pharma sector—Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. But that won’t lead to growth of Bayer’s pharma business overall this year as two contraction drivers—Xarelto and Eylea—are working in the opposite direction.
More: Bayer looking at another year of 'resilience' before growth kicks in behind Nubeqa, Kerendia
Source: fierce